Take-at-home drug for chronic lymphocytic leukaemia recommended by NICE
A new NICE recommendation introduces a take-at-home treatment for chronic lymphocytic leukaemia, reducing the need for hospital visits and offering a chemotherapy-free option.
Introduction
The National Institute for Health and Care Excellence (NICE) has recommended a new take-at-home treatment for chronic lymphocytic leukaemia (CLL). The drug, pirtobrutinib provides a targeted, chemotherapy-free option that can be taken orally, offering greater convenience and potentially improved quality of life for some patients with relapsed or refractory CLL Draft recommendations are now open for public consultation until 5 pm on Monday, 11 May.
What is the take-at-home treatment for chronic lymphocytic leukaemia?
Pirtobrutinib is an oral targeted therapy taken as a tablet. It is designed to treat CLL by interfering with cancer cell survival pathways, offering an alternative to traditional chemotherapy-based regimens.
Unlike many existing treatments that require intravenous administration in hospital, pirtobrutinib can be taken at home, reducing the burden of frequent hospital visits.
Who is eligible for pirtobrutinib?
NICE recommends pirtobrutinib for adults with chronic lymphocytic leukaemia who:
- Relapsed or refractory CLL in those who have been previously treated with a BTK inhibitor
Why this recommendation matters for patient care
The introduction of a take-at-home treatment marks a shift towards more patient-centred care in oncology.
Reducing the need for hospital-based intravenous therapy also helps minimise disruption to daily life and lowers the risk of hospital-related complications.
Conclusion
NICE’s recommendation of pirtobrutinib represents a significant advancement in the management of chronic lymphocytic leukaemia. By offering a targeted, chemotherapy-free treatment that can be taken at home, it supports improved patient experience while maintaining clinical effectiveness. This aligns with broader NHS priorities to enhance access, reduce hospital dependency, and deliver more personalised care.
Citation
Recent Resources
